B T Hennessy

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Non-Hodgkin lymphoma: an update
    Bryan T Hennessy
    Department of Medical Oncology, St James Hospital, Dublin, Ireland
    Lancet Oncol 5:341-53. 2004
  2. ncbi Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy
    Bryan T Hennessy
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1000-6. 2006
  3. ncbi Ovarian cancer: homeobox genes, autocrine/paracrine growth, and kinase signaling
    B T Hennessy
    Department of Molecular Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Biochem Cell Biol 38:1450-6. 2006
  4. pmc RPPAML/RIMS: a metadata format and an information management system for reverse phase protein arrays
    Romesh Stanislaus
    Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    BMC Bioinformatics 9:555. 2008
  5. ncbi Pharmacodynamic markers of perifosine efficacy
    Bryan T Hennessy
    Department of Systems Biology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 13:7421-31. 2007
  6. ncbi Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy
    Bryan T Hennessy
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 23:9304-11. 2005
  7. doi A systems approach to analysis of molecular complexity in breast cancer
    Bryan T Hennessy
    Department of Systems Biology and the Kleberg Center for Molecular Markers, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 15:417-9. 2009
  8. ncbi Biphasic metaplastic sarcomatoid carcinoma of the breast
    B T Hennessy
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Ann Oncol 17:605-13. 2006
  9. ncbi Squamous cell carcinoma of the breast
    Bryan T Hennessy
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    J Clin Oncol 23:7827-35. 2005
  10. ncbi Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature
    B T Hennessy
    Department of Breast Medical Oncology and Division of Pharmacy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 16:1289-96. 2005

Detail Information

Publications35

  1. ncbi Non-Hodgkin lymphoma: an update
    Bryan T Hennessy
    Department of Medical Oncology, St James Hospital, Dublin, Ireland
    Lancet Oncol 5:341-53. 2004
    ..Here, we review advances in the treatment of NHL that have occurred over the past 10 years...
  2. ncbi Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy
    Bryan T Hennessy
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1000-6. 2006
    ..The purpose of the current study was to determine long-term outcome in patients achieving a pCR of cytologically proven inflammatory breast carcinoma ALN metastases after primary chemotherapy...
  3. ncbi Ovarian cancer: homeobox genes, autocrine/paracrine growth, and kinase signaling
    B T Hennessy
    Department of Molecular Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Biochem Cell Biol 38:1450-6. 2006
    ..As the disease progresses, activation of kinase pathways and continued abnormal autocrine/paracrine stimulation contribute to genomic instability but also identify potential targets for novel therapeutic intervention...
  4. pmc RPPAML/RIMS: a metadata format and an information management system for reverse phase protein arrays
    Romesh Stanislaus
    Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    BMC Bioinformatics 9:555. 2008
    ..Up to 100 different proteins may be assessed using immunoperoxidase or immunoflorescence techniques in order to determine relative amounts of protein expression in the samples of interest...
  5. ncbi Pharmacodynamic markers of perifosine efficacy
    Bryan T Hennessy
    Department of Systems Biology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 13:7421-31. 2007
    ..Recent studies suggest that perifosine inhibits the phosphatidylinositol-3'-kinase (PI3K) pathway by preventing cell membrane recruitment of the AKT pleckstrin homology domain...
  6. ncbi Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy
    Bryan T Hennessy
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 23:9304-11. 2005
    ..The purpose of this study was to determine long-term outcome in patients achieving pCR of cytologically proven axillary lymph node (ALN) metastases...
  7. doi A systems approach to analysis of molecular complexity in breast cancer
    Bryan T Hennessy
    Department of Systems Biology and the Kleberg Center for Molecular Markers, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 15:417-9. 2009
    ..They identify distinct copy number anomaly patterns in different breast cancer subtypes that implicate a number of genes as potential therapeutic targets and as potential markers of therapy responsiveness...
  8. ncbi Biphasic metaplastic sarcomatoid carcinoma of the breast
    B T Hennessy
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Ann Oncol 17:605-13. 2006
    ..D. Anderson Cancer Center (MDACC) with 213 MSC and 98 carcinosarcoma patients identified through the Surveillance, Epidemiology and End-Results (SEER) database to describe clinical and pathologic characteristics...
  9. ncbi Squamous cell carcinoma of the breast
    Bryan T Hennessy
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    J Clin Oncol 23:7827-35. 2005
    ..D. Anderson Cancer Center (Houston, TX) and a series of 137 patients identified through the Surveillance, Epidemiology, and End Results (SEER) database to make therapy recommendations...
  10. ncbi Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature
    B T Hennessy
    Department of Breast Medical Oncology and Division of Pharmacy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 16:1289-96. 2005
    ..We also reviewed the safety profile of capecitabine at these doses and performed a safety review of capecitabine in phase II and III metastatic breast and colorectal cancer trials...
  11. pmc Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics
    Bryan T Hennessy
    Department of Gynecologic Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 69:4116-24. 2009
    ..PIK3CA mutations, EMT, and stem cell-like characteristics likely contribute to the poor outcomes of MBC and suggest novel therapeutic targets...
  12. pmc Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer
    Roshan Agarwal
    The University of Texas M D Anderson Cancer Center MDACC, Houston, Texas, USA
    Clin Cancer Res 15:3654-62. 2009
    ..We studied the expression levels of cyclins B1, D1, and E1 and the implications of cyclin overexpression for patient outcomes in distinct breast cancer subtypes defined by clinical variables and transcriptional profiling...
  13. pmc Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer
    Chad J Creighton
    Dan L Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Breast Cancer Res 12:R40. 2010
    ..We thus examined whether deregulated PI3K signaling in luminal ER+ breast tumors is associated with ER level and activity and intrinsic molecular subtype...
  14. doi Quantitative proteomic analysis in breast cancer
    A Tabchy
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Drugs Today (Barc) 47:169-82. 2011
    ..Several initial successes in breast cancer are showing that such information is clinically relevant...
  15. pmc Rak functions as a tumor suppressor by regulating PTEN protein stability and function
    Eun Kyoung Yim
    Department of Systems Biology, The University of Texas M D Anderson Cancer Center, Houston, TX 77054, USA
    Cancer Cell 15:304-14. 2009
    ..Furthermore, Rak knockdown was sufficient to transform normal mammary epithelial cells. Therefore, Rak acts as a bona fide tumor suppressor gene through the mechanism of regulating PTEN protein stability and function...
  16. doi Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 15:2472-8. 2009
    ..To examine the androgen receptor (AR) levels in breast cancer and to assess the impact of AR expression on patient outcomes...
  17. pmc Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy
    Mark S Carey
    Department of Systems Biology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 16:2852-60. 2010
    ..Using reverse phase protein array, we measured protein expression associated with response to primary chemotherapy in patients with advanced-stage, high-grade serous ovarian cancer...
  18. ncbi Trends for inflammatory breast cancer: is survival improving?
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030 4009, USA
    Oncologist 12:904-12. 2007
    ..Clinical trials focusing on the management of this aggressive disease are warranted. Disclosure of potential conflicts of interest is found at the end of this article...
  19. pmc Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 17:1082-9. 2011
    ..Survival was estimated by Kaplan-Meier method and compared with log-rank. Cox proportional hazards models were fit to determine the independent association of mutation status with outcome...
  20. pmc Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer
    Siqing Fu
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:1661-9. 2011
    ..A phase 1b-2a clinical trial of this sequential combination of azacitidine and carboplatin was initiated in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer...
  21. pmc Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis
    Mandi M Murph
    Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 4:e5583. 2009
    ..However, there is an absence of systematic data critically analyzing the transcriptional changes induced by LPA in ovarian cancer...
  22. pmc An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
    Katherine Stemke-Hale
    Department of Systems Biology, The University of Texas MD Anderson Cancer, Houston, Texas 77030, USA
    Cancer Res 68:6084-91. 2008
    ..The specific aberration present may have implications for the selection of PI3K-targeted therapies in hormone receptor-positive breast cancer...
  23. ncbi Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials
    Emer O Hanrahan
    Department of Breast Medical Oncology, Unit 1354, UT MD Anderson Cancer Center, PO Box 301439, Houston, Texas 77230 1439, USA
    Expert Opin Pharmacother 6:1477-91. 2005
    ....
  24. doi Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set
    Eun Sung Park
    Department of Melanoma Medical Oncology and Department of Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0904, Houston, TX 77030, USA
    Mol Cancer Ther 9:257-67. 2010
    ....
  25. ncbi Individualization of neoadjuvant therapy for breast cancer according to molecular tumor characteristics
    Bryan T Hennessy
    University of Texas MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    Nat Clin Pract Oncol 2:598-9. 2005
  26. ncbi Adjuvant therapy for breast cancer
    B T Hennessy
    Department of Breast Medical Oncology, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Minerva Ginecol 57:305-26. 2005
    ..Results from several large randomized studies are expected shortly and will define the use of trastuzumab in this clinical setting...
  27. ncbi Exploiting the PI3K/AKT pathway for cancer drug discovery
    Bryan T Hennessy
    Department of Molecular Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Nat Rev Drug Discov 4:988-1004. 2005
    ..This warrants exploiting the PI3K/AKT pathway for cancer drug discovery...
  28. doi Ovarian cancer
    Bryan T Hennessy
    Department of Gynecologic Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet 374:1371-82. 2009
    ....
  29. doi Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach
    Matthias Niedermeier
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    Blood 113:5549-57. 2009
    ....
  30. pmc Ovarian cancer: linking genomics to new target discovery and molecular markers--the way ahead
    Bryan T Hennessy
    Department of Molecular Therapeutics, MD Anderson Cancer Center, Houston, TX, USA
    Adv Exp Med Biol 617:23-40. 2008
  31. doi Breast carcinoma with neuroendocrine differentiation and myocardial metastases
    Bryan T Hennessy
    Department of Gynecologic Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Clin Breast Cancer 7:892-4. 2007
    ..Better understanding of the cellular origin and molecular pathogenesis of this relatively enigmatic rare disease is required...
  32. ncbi New approaches in the treatment of myelofibrosis
    Bryan T Hennessy
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 103:32-43. 2005
    ..g., thalidomide), tyrosine kinase inhibitors (e.g., imatinib mesylate), farnesyl transferase inhibitors (e.g., R115777), and other agents are reviewed, in addition to the potential roles of autologous and allogeneic SCT...
  33. ncbi DNA methylation in haematological malignancies: the role of decitabine
    Bryan T Hennessy
    Department of Leukaemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Expert Opin Investig Drugs 12:1985-93. 2003
    ..Phase II and III studies are currently ongoing to evaluate decitabine, both alone and in combination, in various stages of these haematological malignancies...
  34. ncbi A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
    Katrien Berns
    Division of Molecular Carcinogenesis and Center for Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Cancer Cell 12:395-402. 2007
    ..Thus, assessment of PI3K pathway activation may provide a biomarker to identify patients unlikely to respond to trastuzumab-based therapy...
  35. ncbi Primary angiosarcomas of the breast
    Taimur Sher
    Department of Internal Medicine, Mount Sinai Medical Center, Miami Beach, Florida, USA
    Cancer 110:173-8. 2007
    ..The purpose of the study was to describe the clinicopathologic characteristics and clinical outcomes of patients with primary breast angiosarcoma...